Qiagen (NYSE:QGEN) Q1 2026 earnings snapshot

Qiagen (NYSE:QGEN) opened 2026 with Q1 revenue of US$492.3 million and basic EPS of US$0.33, setting a clear reference point against the current share price of US$33.51. The company reported quarterly revenue of US$483.5 million in Q1 2025 compared with US$492.3 million in Q1 2026, while basic EPS moved from US$0.44 to US$0.33 over the same period, with trailing 12 month EPS at US$1.95. With net profit margin reported at 20.3% over the last year, the latest results place profitability and margin quality firmly in focus for investors.

See our full analysis for Qiagen.

With the headline numbers reported, the next step is to compare these earnings with the widely followed narratives around Qiagen's growth, risks, and profit sustainability to see which views align with the latest figures and which may be called into question.

20.3% net margin contrasts with softer quarterly profit

• Over the last 12 months Qiagen generated US$402.2 million of net income on US$2.1b of revenue, a 20.3% net margin, while Q1 2026 quarterly net income of US$68.0 million compares with US$90.8 million in Q1 2025.
• Bears focus on weaker life sciences funding and softer demand for higher margin instruments, and this cautious view lines up with the gap between the strong trailing margin and the lower Q1 2026 net income, which limits the evidence that recent profitability trends are flowing evenly through every quarter.
  • Critics highlight that trailing earnings grew very quickly over the last year but fell at an annualized rate of 14.1% over five years, so they question how durable the 20.3% margin really is.
  • The bearish narrative also points to potential pressure on gross margins if demand for PCR consumables and newer systems does not absorb fixed investment, which would matter if future quarters look closer to Q1 2026 than to the stronger trailing figures.

Skeptics point to the jump in net margin alongside a weaker five year earnings record as a reason to stay cautious on how long this profitability profile can last, and the full cautious case sets out how product adoption and funding trends could influence that view over time. 🐻 Qiagen Bear Case

TTM EPS near US$1.95 vs quarterly EPS trend

• Trailing 12 month basic EPS is US$1.95, built from quarterly EPS ranging between US$0.33 and US$0.63 over the last five reported quarters, so Q1 2026 sits at the low end of that recent range.
• Analysts who lean optimistic see room for earnings growth supported by diagnostics, automation and bioinformatics, yet the Q1 2026 EPS of about US$0.33, versus US$0.52 to US$0.63 in the prior three quarters, gives you a reminder that the earnings path has been uneven even while the trailing figure looks strong.
  • The consensus narrative points to efficiency efforts and reinvestment as positives, and the 12 month EPS of US$1.95 reflects that, but the lower latest quarter shows how short term swings can differ from the multi year story.
  • Bulls also highlight recurring consumables and software as supports for profitability, which is consistent with the solid trailing EPS, although the quarterly step down leaves open how quickly those areas may offset any softer demand in research budgets and China.

Bulls argue that product mix and recurring revenue can keep EPS on an upward path over time, and the full optimistic narrative walks through how diagnostics and automation could matter for that view relative to the recent quarterly run rate. 🐂 Qiagen Bull Case

Valuation gap vs DCF and 46.32 analyst target

• At a share price of US$33.51, Qiagen trades on a 16.8x P/E that is below peer and industry averages and below a cited DCF fair value of about US$64.80, and it also sits under the single allowed analyst price target of US$46.32.
• Consensus narrative supporters point to this combination of a lower than peer P/E and a discount to both DCF fair value and the US$46.32 target as evidence that the market is pricing in the weaker five year earnings trend and dividend coverage concerns more than the recent 20.3% margin and sharp trailing year earnings growth.
  • The data shows earnings for the last 12 months rising very strongly versus the prior year, yet the 5 year annualized change is a 14.1% decline, which can help explain why the current multiple is below industry levels.
  • At the same time, forecasts for about 6.3% revenue growth and roughly 12.1% earnings growth sit below the broader US market assumptions, so supporters of the consensus view may see the valuation gap as tied to those moderated expectations rather than only to company specific issues.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Qiagen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed signals or clear opportunity: that is the question investors are wrestling with, so look through the figures, compare the narratives, and then weigh up the 4 key rewards and 1 important warning sign

See What Else Is Out There

Qiagen's weaker Q1 2026 EPS, softer quarterly net income versus the prior year, and declining 5 year earnings record highlight pressure on profit consistency.

If that uneven profile makes you cautious, broaden your watchlist with 74 resilient stocks with low risk scores that focus on steadier earnings and lower risk scores so you are not relying on a single story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.